These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 20350941)

  • 1. Evaluation of Etest to determine tigecycline MICs for Enterobacter species.
    Cohen Stuart J; Mouton JW; Diederen BM; Al Naiemi N; Thijsen S; Vlaminckx BJ; Fluit AC; Leverstein-van Hall MA
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2746-7. PubMed ID: 20350941
    [No Abstract]   [Full Text] [Related]  

  • 2. Genetic characterization of tigecycline resistance in clinical isolates of Enterobacter cloacae and Enterobacter aerogenes.
    Veleba M; De Majumdar S; Hornsey M; Woodford N; Schneiders T
    J Antimicrob Chemother; 2013 May; 68(5):1011-8. PubMed ID: 23349441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emergence of AcrAB-mediated tigecycline resistance in a clinical isolate of Enterobacter cloacae during ciprofloxacin treatment.
    Hornsey M; Ellington MJ; Doumith M; Scott G; Livermore DM; Woodford N
    Int J Antimicrob Agents; 2010 May; 35(5):478-81. PubMed ID: 20189357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colistin resistance in Enterobacter spp. isolates in Korea.
    Hong YK; Lee JY; Ko KS
    J Microbiol; 2018 Jun; 56(6):435-440. PubMed ID: 29858832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the Rapid Polymyxin NP Test for Polymyxin B Resistance Detection Using Enterobacter cloacae and Enterobacter aerogenes Isolates.
    Simar S; Sibley D; Ashcraft D; Pankey G
    J Clin Microbiol; 2017 Oct; 55(10):3016-3020. PubMed ID: 28747375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Snapshot of Co-Resistance to Carbapenems and Tigecycline in Clinical Isolates of Enterobacter cloacae.
    Huang LF; Lee CT; Su LH; Chang CL
    Microb Drug Resist; 2017 Jan; 23(1):1-7. PubMed ID: 27136494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo activities of tigecycline-colistin combination therapies against carbapenem-resistant Enterobacteriaceae.
    Betts JW; Phee LM; Hornsey M; Woodford N; Wareham DW
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3541-6. PubMed ID: 24687491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro susceptibility of multidrug-resistant Enterobacteriaceae clinical isolates to tigecycline.
    Huang TD; Berhin C; Bogaerts P; Glupczynski Y
    J Antimicrob Chemother; 2012 Nov; 67(11):2696-9. PubMed ID: 22833638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro susceptibility to 19 agents other than β-lactams among third-generation cephalosporin-resistant Enterobacteriaceae recovered on hospital admission.
    Mischnik A; Baumert P; Hamprecht A; Rohde AM; Peter S; Feihl S; Knobloch J; Gölz H; Kola A; Obermann B; Querbach C; Willmann M; Gebhardt F; Tacconelli E; Gastmeier P; Seifert H; Kern WV;
    J Antimicrob Chemother; 2017 May; 72(5):1359-1363. PubMed ID: 28108677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of tigecycline against clinical isolates of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae, Serratia marcescens and Enterobacter cloacae.
    Ku YH; Chuang YC; Yu WL
    J Microbiol Immunol Infect; 2008 Aug; 41(4):332-6. PubMed ID: 18787741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
    Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of media and testing methodology on susceptibility to tigecycline of Enterobacteriaceae with reported high tigecycline MIC.
    Torrico M; González N; Giménez MJ; Alou L; Sevillano D; Navarro D; Díaz-Antolín MP; Larrosa N; Aguilar L; Garcia-Escribano N
    J Clin Microbiol; 2010 Jun; 48(6):2243-6. PubMed ID: 20351208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single daily high-dose tigecycline therapy of a multidrug-resistant (MDR) Klebsiella pneumoniae and Enterobacter aerogenes nosocomial urinary tract infection.
    Cunha BA; McDermott B; Nausheen S
    J Chemother; 2007 Dec; 19(6):753-4. PubMed ID: 18230562
    [No Abstract]   [Full Text] [Related]  

  • 14. Detection of virulence and β-lactamase encoding genes in Enterobacter aerogenes and Enterobacter cloacae clinical isolates from Brazil.
    Azevedo PAA; Furlan JPR; Oliveira-Silva M; Nakamura-Silva R; Gomes CN; Costa KRC; Stehling EG; Pitondo-Silva A
    Braz J Microbiol; 2018 Nov; 49 Suppl 1(Suppl 1):224-228. PubMed ID: 29858139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid Polymyxin NP test for the detection of polymyxin resistance mediated by the mcr-1/mcr-2 genes.
    Poirel L; Larpin Y; Dobias J; Stephan R; Decousser JW; Madec JY; Nordmann P
    Diagn Microbiol Infect Dis; 2018 Jan; 90(1):7-10. PubMed ID: 29146285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discordance in the minimal inhibitory concentrations of ertapenem for Enterobacter cloacae: Vitek 2 system versus Etest and agar dilution methods.
    Pailhoriès H; Cassisa V; Lamoureux C; Chesnay A; Lebreton C; Lemarié C; Kempf M; Mahaza C; Joly-Guillou ML; Eveillard M
    Int J Infect Dis; 2014 Jan; 18():94-6. PubMed ID: 24183718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergence of an Enterobacter hormaechei strain with reduced susceptibility to tigecycline under tigecycline therapy.
    Daurel C; Fiant AL; Brémont S; Courvalin P; Leclercq R
    Antimicrob Agents Chemother; 2009 Nov; 53(11):4953-4. PubMed ID: 19738023
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of the clinical and microbiologic characteristics of patients with Enterobacter cloacae and Enterobacter aerogenes bacteremia: a prospective observation study.
    Song EH; Park KH; Jang EY; Lee EJ; Chong YP; Cho OH; Kim SH; Lee SO; Sung H; Kim MN; Jeong JY; Kim YS; Woo JH; Choi SH
    Diagn Microbiol Infect Dis; 2010 Apr; 66(4):436-40. PubMed ID: 20071128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of plasmid-mediated quinolone resistance genes in clinical isolates of Enterobacter spp. in Spain.
    Cano ME; Rodríguez-Martínez JM; Agüero J; Pascual A; Calvo J; García-Lobo JM; Velasco C; Francia MV; Martínez-Martínez L
    J Clin Microbiol; 2009 Jul; 47(7):2033-9. PubMed ID: 19386836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clonality, outer-membrane proteins profile and efflux pump in KPC- producing Enterobacter sp. in Brazil.
    Rosa JF; Rizek C; Marchi AP; Guimaraes T; Miranda L; Carrilho C; Levin AS; Costa SF
    BMC Microbiol; 2017 Mar; 17(1):69. PubMed ID: 28302074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.